Research

Engineering of crystalline combination inhalation particles of a long-acting β2-agonist and a corticosteroid


Reference:

Pitchayajittipong, C., Shur, J. and Price, R., 2009. Engineering of crystalline combination inhalation particles of a long-acting β2-agonist and a corticosteroid. Pharmaceutical Research, 26 (12), pp. 2657-2666.

Related documents:

This repository does not currently have the full-text of this item.
You may be able to access a copy if URLs are provided below. (Contact Author)

Official URL:

http://dx.doi.org/10.1007/s11095-009-9982-3

Abstract

Purpose: Engineering of inhalation particles incorporating, in each individual particle, a combination of a long-acting β-agonist and a glucocorticosteroid in a pre-determined and constant ratio for delivery via a dry powder inhaler (DPI). Methods: Individual crystalline particles containing both the glucocorticosteroid fluticasone propionate (FP) and long-acting β-agonist salmeterol (SX) were prepared, in a ratio of 10:1, using the solution atomization and crystallization by sonication (SAX) process. Combination drug particles were characterized by particle size, morphology, crystallinity and aerosolisation efficiency using inertial impaction. Results: Combination drug particles were spherical and crystalline, with a median diameter of 4.68 ± 0.01 μm. Aerosolisation of formulations containing combination drug particles resulted in greater uniformity in delivery ratios of both actives across all stages of the impactor before and after storage. Conclusions: Actives in a pre-determined dose ratio can be crystallised in a single particle using the SAX process.

Details

Item Type Articles
CreatorsPitchayajittipong, C., Shur, J. and Price, R.
DOI10.1007/s11095-009-9982-3
DepartmentsFaculty of Science > Pharmacy & Pharmacology
RefereedYes
StatusPublished
ID Code26918

Export

Actions (login required)

View Item